Peritoneal ultrafiltration and serum icodextrin concentration during dialysis with 7.5% icodextrin solution in Japanese patients
- PMID: 12968843
Peritoneal ultrafiltration and serum icodextrin concentration during dialysis with 7.5% icodextrin solution in Japanese patients
Abstract
Objectives: To assess the efficacy and safety of icodextrin in Japanese patients and to investigate the relationship between net ultrafiltration (UF) during the long dwell and plasma oligosaccharides.
Design: Open-labeled clinical trial involving patients on continuous ambulatory peritoneal dialysis (CAPD) receiving icodextrin during the 12-hour long dwell for 6 weeks, preceded by and followed by a 2-week baseline period and a follow-up period during which 1.36% glucose was used for the 8-hour long dwell.
Setting: A prospective, randomized multicenter study done in tertiary medical centers.
Patients: 18 stable patients on CAPD for 3 months or longer.
Main outcomes measures: Net UF (in milliliters), UF rate (in milliliters per hour), plasma oligosaccharides, serum osmolarity (in milliosmoles per liter), peritoneal absorption of icodextrin, and peritoneal clearances of icodextrin, creatinine, and urea were assessed. Adverse events, laboratory findings, and vital signs were also monitored.
Results: Long-dwell net UF (544.4 +/- 96.7 mL at day 3, p < 0.001; 309.4 +/- 60.7 mL at week 4, p < 0.001; and 391.7 +/- 61.1 mL at week 6, p < 0.001) and UF rate (48.2 +/- 38.8 mL/ hour at day 3, p < 0.001; 26.9 +/- 22.1 mL/hr at week 4, p < 0.002; and 35.3 +/- 22.9 mL/hr at week 6, p = 0.0002) were significantly greater during the icodextrin period than at baseline (-25.9 +/- 46.0 mL and -2.2 +/- 22.1 mL/hr, respectively). Plasma oligosaccharides reached steady state within 2 weeks, remained stable during the treatment period, and returned to baseline level 2 weeks after discontinuation of icodextrin. Serum osmolarity increased during the use of icodextrin by approximately 5 mOsm/L. No statistically significant relationship was found between plasma oligosaccharides and net UF. Peritoneal absorption of icodextrin (36.3% +/- 5.1% at day 3, 42.2% +/- 5.9% at week 4, and 38.0% +/- 6.3% at week 6) and peritoneal clearance of icodextrin (10.1 mL/minute at day 3, 10.1 mL/min at week 4, and 10.3 mL/min at week 6) showed no major change over time. Serum sodium and serum chloride both decreased by 5 mEq/L with icodextrin but remained within the normal range during the treatment period and returned to baseline levels immediately after discontinuation. No serious adverse events were observed during the study.
Conclusion: The results of this study do not support the hypothesis that an increased blood oligosaccharide level and the concomitant elevation in serum osmolarity have a negative impact on peritoneal UF. Therefore, the increase in plasma oligosaccharides appears to be too small to be of clinical significance.
Similar articles
-
Assessment of the effectiveness, safety, and biocompatibility of icodextrin in automated peritoneal dialysis. The Dextrin in APD in Amsterdam (DIANA) Group.Perit Dial Int. 2000;20 Suppl 2:S106-13. Perit Dial Int. 2000. PMID: 10911654 Clinical Trial.
-
Icodextrin: a review of its use in peritoneal dialysis.Drugs. 2003;63(19):2079-105. doi: 10.2165/00003495-200363190-00011. Drugs. 2003. PMID: 12962523 Review.
-
Efficacy and safety of a 7.5% icodextrin peritoneal dialysis solution in patients treated with automated peritoneal dialysis.Am J Kidney Dis. 2002 Apr;39(4):862-71. doi: 10.1053/ajkd.2002.32009. Am J Kidney Dis. 2002. PMID: 11920355 Clinical Trial.
-
Superiority of icodextrin compared with 4.25% dextrose for peritoneal ultrafiltration.J Am Soc Nephrol. 2005 Feb;16(2):546-54. doi: 10.1681/ASN.2004090793. Epub 2004 Dec 29. J Am Soc Nephrol. 2005. PMID: 15625070 Clinical Trial.
-
Icodextrin provides long dwell peritoneal dialysis and maintenance of intraperitoneal volume.Artif Organs. 1998 Jan;22(1):8-12. doi: 10.1046/j.1525-1594.1998.06055.x. Artif Organs. 1998. PMID: 9456219 Review.
Cited by
-
Icodextrin and peritoneal dialysis: advantages and new applications.Int Urol Nephrol. 2018 Mar;50(3):495-500. doi: 10.1007/s11255-017-1647-2. Epub 2017 Jul 3. Int Urol Nephrol. 2018. PMID: 28674854 Review.
-
Predicting the Peritoneal Absorption of Icodextrin in Rats and Humans Including the Effect of α-Amylase Activity in Dialysate.Perit Dial Int. 2015 May-Jun;35(3):288-96. doi: 10.3747/pdi.2012.00247. Epub 2014 Mar 1. Perit Dial Int. 2015. PMID: 24584610 Free PMC article.
-
Bimodal solutions or twice-daily icodextrin to enhance ultrafiltration in peritoneal dialysis patients.Int J Nephrol. 2013;2013:424915. doi: 10.1155/2013/424915. Epub 2013 Jan 8. Int J Nephrol. 2013. PMID: 23365749 Free PMC article.
-
Comparison of volume status in asymptomatic haemodialysis and peritoneal dialysis outpatients.Nephron Extra. 2012 Jan;2(1):48-54. doi: 10.1159/000337338. Epub 2012 Mar 26. Nephron Extra. 2012. PMID: 22619667 Free PMC article.
-
Renal Association Clinical Practice Guideline on peritoneal dialysis in adults and children.BMC Nephrol. 2017 Nov 16;18(1):333. doi: 10.1186/s12882-017-0687-2. BMC Nephrol. 2017. PMID: 29145808 Free PMC article.